Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wuhan YZY Biopharma CoHKSE:02496 Days Payable is 28.03 as of Dec. 2025, which is 50% below its 10-year median of 55.84. The stock has 8 warning signs investors should review. Among 702 Biotechnology companies, Wuhan YZY Biopharma Co ranks worse than 79.63% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02496 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Wuhan YZY Biopharma Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wuhan YZY Biopharma Co Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Wuhan YZY Biopharma Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Wuhan YZY Biopharma Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Wuhan YZY Biopharma Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wuhan YZY Biopharma Co (HKSE:02496) has a Days Payable of 28.03 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Wuhan YZY Biopharma Co and its competitors. This is 50% below median its historical median of 55.84. Over the past decade, Wuhan YZY Biopharma Co's Days Payable has ranged from 31.54 to 76.57. According to the industry distribution chart, Wuhan YZY Biopharma Co ranks #559 out of 702 companies in the Biotechnology industry, placing it in the top 79.6%.
Is Wuhan YZY Biopharma Co's Days Payable too high?
Wuhan YZY Biopharma Co's current Days Payable of 28.03 is 50% below median its 10-year median of 55.84. Over the past 10 years, this metric has ranged from a low of 31.54 to a high of 76.57. The Biotechnology industry median Days Payable is 113.10. Wuhan YZY Biopharma Co's value of 28.03 is 75.2% below this industry median. Based on the distribution chart, Wuhan YZY Biopharma Co ranks #559 out of 702 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Wuhan YZY Biopharma Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Wuhan YZY Biopharma Co ranks #559 out of 702 companies for Days Payable. This places Wuhan YZY Biopharma Co in the lower half of its industry. The industry median Days Payable is 113.10. Wuhan YZY Biopharma Co's value of 28.03 is 75.2% below this benchmark. Historically, Wuhan YZY Biopharma Co's own Days Payable has ranged from 31.54 to 76.57 over the past decade. While the company's 10-year median is 55.84 vs. the industry median of 113.10, Wuhan YZY Biopharma Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wuhan YZY Biopharma Co's current Days Payable of 28.03 is 75.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Wuhan YZY Biopharma Co and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wuhan YZY Biopharma Co's current Days Payable is 28.03, which is 50% below median its own 10-year median of 55.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuhan YZY Biopharma Co stock overvalued right now?
Wuhan YZY Biopharma Co (HKSE:02496) has a current Days Payable of 28.03. The current Days Payable is 28.03, which is 50% below median its 10-year median of 55.84 and 75.2% below the Biotechnology industry median of 113.10. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Wuhan YZY Biopharma Co (HKSE:02496), the current Days Payable is 28.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Wuhan YZY Biopharma Co Ltd is a biotechnology company dedicated to developing bispecific antibody (BsAb)- based therapies. The Company has been forward-looking in deploying its presence in several therapeutic fields, including but not limited to tumor-associated complications, tumors, ophthalmology, and autoimmune diseases. The Company also proactively established several self-developed technology platforms, such as Y-BODY, Check-Body, and Nano-Ybody, promoting the development of more candidates to clinical stages with high efficiency.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02496 has been successfully added to your 
